FMS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 12, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 31 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 69%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FMS as a result. In 48 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.
FMS moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for FMS moved below the 200-day moving average on October 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for FMS crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where FMS advanced for three days, in 193 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 148 of 266 cases where FMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.992) is normal, around the industry mean (204.532). P/E Ratio (14.096) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.741) is also within normal values, averaging (2.498). Dividend Yield (0.149) settles around the average of (0.154) among similar stocks. P/S Ratio (0.574) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. FMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 78 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Stochastic Oscillator for MD moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 59 similar instances where the indicator exited the overbought zone. In 47 of the 59 cases the stock moved lower. This puts the odds of a downward move at 80%.
The 10-day RSI Indicator for MD moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 19 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Moving Average Convergence Divergence Histogram (MACD) for MD turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 32 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
MD broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The 10-day moving average for MD crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.
Following a +1.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where MD advanced for three days, in 195 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 135 of 198 cases where MD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. MD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.886) is normal, around the industry mean (204.532). P/E Ratio (14.690) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (1.119) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
FMS | MD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 54 | 89 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 84 | |
SMR RATING 1..100 | 78 | 46 | |
PRICE GROWTH RATING 1..100 | 57 | 37 | |
P/E GROWTH RATING 1..100 | 65 | 22 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FMS's Valuation (6) in the Medical Or Nursing Services industry is somewhat better than the same rating for MD (61). This means that FMS’s stock grew somewhat faster than MD’s over the last 12 months.
MD's Profit vs Risk Rating (84) in the Medical Or Nursing Services industry is in the same range as FMS (100). This means that MD’s stock grew similarly to FMS’s over the last 12 months.
MD's SMR Rating (46) in the Medical Or Nursing Services industry is in the same range as FMS (78). This means that MD’s stock grew similarly to FMS’s over the last 12 months.
MD's Price Growth Rating (37) in the Medical Or Nursing Services industry is in the same range as FMS (57). This means that MD’s stock grew similarly to FMS’s over the last 12 months.
MD's P/E Growth Rating (22) in the Medical Or Nursing Services industry is somewhat better than the same rating for FMS (65). This means that MD’s stock grew somewhat faster than FMS’s over the last 12 months.
| FMS | MD | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 70% |
| Stochastic ODDS (%) | 2 days ago 53% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 61% | N/A |
| MACD ODDS (%) | 2 days ago 69% | 2 days ago 71% |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 62% | 2 days ago 66% |
| Advances ODDS (%) | 14 days ago 61% | 9 days ago 65% |
| Declines ODDS (%) | 2 days ago 64% | 6 days ago 70% |
| BollingerBands ODDS (%) | N/A | 2 days ago 70% |
| Aroon ODDS (%) | 2 days ago 56% | 2 days ago 68% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FMS’s FA Score shows that 1 FA rating(s) are green while MD’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FMS’s TA Score shows that 4 TA indicator(s) are bullish while MD’s TA Score has 3 bullish TA indicator(s).
FMS (@Hospital/Nursing Management) experienced а -4.62% price change this week, while MD (@Hospital/Nursing Management) price change was -1.55% for the same time period.
The average weekly price growth across all stocks in the @Hospital/Nursing Management industry was -10.44%. For the same industry, the average monthly price growth was -7.09%, and the average quarterly price growth was +3.25%.
FMS is expected to report earnings on Feb 23, 2027.
MD is expected to report earnings on Feb 18, 2027.
Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.
A.I.dvisor indicates that over the last year, FMS has been loosely correlated with DVA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if FMS jumps, then DVA could also see price increases.
A.I.dvisor indicates that over the last year, MD has been loosely correlated with UHS. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if MD jumps, then UHS could also see price increases.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SPCF | 13.54 | 0.80 | +6.28% |
| ProShares Ultra SpaceX ETF (SPCF) | |||
| PSEP | 45.82 | -0.26 | -0.56% |
| Innovator U.S. Equity Power Buffer ETF - September (PSEP) | |||
| IBFR | 49.34 | -0.36 | -0.73% |
| Innovator International Developed Managed 10 Buffer ETF (IBFR) | |||
| PTH | 55.35 | -0.55 | -0.99% |
| Invesco Dorsey Wright Healthcare Momentum ETF (PTH) | |||
| MSR | 11.89 | -0.63 | -5.06% |
| GraniteShares Autocallable MSTR ETF (MSR) | |||